文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

氢化可的松、维生素C与硫胺素(HAT)治疗脓毒症与脓毒性休克:一项带试验序贯分析的Meta分析

Hydrocortisone, ascorbic acid, and thiamine (HAT) for sepsis and septic shock: a meta-analysis with sequential trial analysis.
PubMed 文献 · J Intensive Care · 2021-12-18
一句话结论9项RCT共1427例脓毒症/脓毒性休克患者,HAT方案改善72小时SOFA评分并缩短血管升压药使用时间,但住院死亡率和28/30天死亡率无显著差异。

该Meta分析检索Ovid MEDLINE、Embase和Cochrane Central Register of Controlled Trials(自建库至2021年8月14日),纳入9项RCT、1427例脓毒症与脓毒性休克患者(HAT组717例,仅标准治疗组710例)。主要终点72小时SOFA评分变化有显著差异(MD 0.65,95%CI 0.30至1.00),血管升压药使用时间(MD -18.16,95%CI -25.65至-10.68)和PCT清除率(MD 14.54,95%CI 0.64至28.43)也有显著差异。住院死亡率(RR 1.07,95%CI 0.85至1.34)、28/30天死亡率(RR 0.96,95%CI 0.80至1.15)、住院时间(MD 0.78,95%CI -0.30至1.86)和ICU时间(MD 0.12,95%CI -0.53至0.78)无显著差异。作者认为HAT组合改善早期SOFA评分并缩短血管升压药时间,但SOFA评分平均差异较小,未观察到死亡获益。

要点

  • 9项RCT共1427例脓毒症/脓毒性休克患者,HAT组717例 vs 仅标准治疗组710例,72小时SOFA评分变化MD 0.65(95%CI 0.30至1.00)。
  • HAT组血管升压药使用时间缩短,MD -18.16(95%CI -25.65至-10.68)。
  • HAT组PCT清除率提高,MD 14.54(95%CI 0.64至28.43)。
  • 住院死亡率(RR 1.07,95%CI 0.85至1.34)与28/30天死亡率(RR 0.96,95%CI 0.80至1.15)均无显著差异。
  • 住院时间(MD 0.78,95%CI -0.30至1.86)与ICU时间(MD 0.12,95%CI -0.53至0.78)无显著差异。

适用人群与场景

  • 脓毒症与脓毒性休克患者,来自9项随机对照试验,共1427例(HAT组717例,仅标准治疗组710例)。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析(含试验序贯分析),检索Ovid MEDLINE、Embase和Cochrane Central Register of Controlled Trials自建库至2021年8月14日,纳入9项RCT、1427例脓毒症与脓毒性休克患者(HAT组717例,仅标准治疗组710例)。
  • 主要终点72小时SOFA评分变化:MD 0.65(95%CI 0.30至1.00),两组差异显著。
  • 血管升压药使用时间:MD -18.16(95%CI -25.65至-10.68),两组差异显著。
  • PCT清除率:MD 14.54(95%CI 0.64至28.43),两组差异显著。
  • 住院死亡率:RR 1.07(95%CI 0.85至1.34),无显著差异。
  • 28/30天死亡率:RR 0.96(95%CI 0.80至1.15),无显著差异。
  • 住院时间:MD 0.78(95%CI -0.30至1.86),无显著差异。
  • ICU时间:MD 0.12(95%CI -0.53至0.78),无显著差异。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与Meta分析,采用Der Simonian-Laird随机效应模型,并进行亚组分析和试验序贯分析;注册号PROSPERO CRD42020203166。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为HAT组合改善脓毒症患者最初72小时的SOFA评分并缩短血管升压药使用时间;鉴于SOFA评分变化的平均差异较小,未观察到死亡获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sepsis is a primary global health threat and costs a lot, requiring effective and affordable treatments. We performed this meta-analysis to explore the treatment of hydrocortisone, ascorbic acid, and thiamine (HAT) in sepsis and septic shock.

METHODS: We searched Ovid MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from inception to August 14, 2021. We included randomized controlled trials (RCTs) that evaluated the HAT treatments in sepsis and septic shock. The primary outcome was the change in SOFA score over the 72 h. The second outcomes were the hospital, and 28-/30-day mortality, the duration of vasopressors, PCT clearance, hospital length of stay (LOS), and ICU LOS. We performed a subgroup analysis and a trial sequential analysis (TSA). The Der Simonian-Laird random-effects models were used to report the pooled risk ratios (RR) or mean difference (MD) with confidence intervals (CI).

RESULTS: Nine RCTs, enrolling 1427 patients of sepsis and septic shock treated with HAT (717) or only standard care (710), were included. There was a significant difference between the two groups in the change in SOFA score over the first 72 h (MD 0.65, 95% CI 0.30 to 1.00), the duration of vasopressors (MD - 18.16, 95% CI - 25.65 to - 10.68) and the PCT clearance (MD 14.54, 95% CI 0.64 to 28.43). In addition, there was no significant difference in the hospital mortality (RR 1.07, 95% CI 0.85 to 1.34), the 28-/30-day mortality (RR 0.96, 95% CI 0.80 to 1.15), the hospital LOS (MD 0.78, 95% CI - 0.30 to 1.86), and ICU LOS (MD 0.12, 95% CI - 0.53 to 0.78).

CONCLUSIONS: The HAT combination improves the SOFA score in the first 72 h and reduces the duration of vasopressors in patients with sepsis. Given the minor mean difference of the change in SOFA score, the mortality benefit has not been observed.

TRIAL REGISTRATION: PROSPERO, CRD42020203166.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Na W, Shen H, Li Y, et al. Hydrocortisone, ascorbic acid, and thiamine (HAT) for sepsis and septic shock: a meta-analysis with sequential trial analysis. J Intensive Care. 2021. PMID: 34922637. doi:10.1186/s40560-021-00589-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。